Directors Shareholding

 
TIDMOBP 
 
Directors Shareholding 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
November 25, 2010 
 
Ondine Biomedical Inc.: Director Shareholding 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 25, 2010) - Ondine Biomedical Inc. ("Ondine" or the "Company") 
(TSX:OBP)(AIM:OBP) today announces that the Company has issued 93,225 common shares. Application has been made 
for the new common shares to be admitted to AIM which is expected to occur on or about 30 November 2010. The 
shares issued include 88,564 shares issued to a Director of the Company and his spouse as outlined below, 
together with the Director's ownership interest in the Company and the combined ownership interest of the 
Director, his spouse, and a company controlled by them: 
 
Name                                                                 Merrill Biel 
Relationship to the Company                                              Director 
Date the transaction was reported to the Company                November 24, 2010 
Date of transaction                                             November 24, 2010 
Nature of the transaction                                  Issuance from treasury 
Type of security acquired                                           Common shares 
Number of securities acquired: 
 By the Director                                                           55,935 
 By the Director's spouse                                                  32,629 
Price per security                                                     Cdn. $0.60 
Nature and extent of each of the above's 
 interest in the transaction                       100% direct ownership interest 
Number of shares held in the Company by 
 the Director immediately subsequent to 
 completion of the transaction                                            409,559 
Percentage direct ownership in the 
 Company of the Director immediately 
 subsequent to completion of the transaction                                 4.79% 
Number of shares held in the Company by 
 the Director, the Director's spouse, and 
 a company controlled by the Director and 
 his spouse immediately subsequent to 
 completion of the transaction.                                           680,579 
Percentage ownership in the Company by 
 the Director, the Director's spouse, and 
 a company controlled by the Director and 
 his spouse immediately subsequent to 
 completion of the transaction (8.32% 
 assuming all options held by the 
 director are exercised)                                                     7.96% 
Close period                                                                   No 
Other                                     The shares are subject to: 
                                         (i)   a regulatory hold period in Canada 
                                               expiring March 25, 2011; 
                                         (ii)  a contractual hold period expiring 
                                               June 7, 2011, and 
                                         (iii) a Reg S restriction in the United 
                                               States 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[phone] 
[e-mail] 
 
OR 
 
Canaccord Genuity Limited 
Ryan Gaffney 
Nominated Adviser 
[phone] 
 
 
 
 
 
Ondine Biomedical Inc.